Published in Hepatol Res on May 01, 2002
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol (2008) 2.36
The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch (2006) 1.40
Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metab Rev (2010) 0.93
Hepatocellular transport proteins and their role in liver disease. World J Gastroenterol (2001) 0.82
Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen. Gut (2004) 0.77
Chemiluminescence quantitative immunohistochemical determination of MRP2 in liver biopsies. J Histochem Cytochem (2005) 0.77
Visual assessment of biliary excretion of Gd-EOB-DTPA in patients with suspected diffuse liver disease - A biopsy-verified prospective study. Eur J Radiol Open (2015) 0.76
Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension. Exp Ther Med (2016) 0.75
Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World J Gastroenterol (2016) 0.75
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology (2012) 2.39
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology (2013) 2.02
Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology (2002) 1.98
BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology (2004) 1.88
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol (2012) 1.84
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol (2008) 1.72
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. Proc Natl Acad Sci U S A (2005) 1.65
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol (2011) 1.57
Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics (2004) 1.56
Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55
Primary biliary cirrhosis. Semin Immunopathol (2009) 1.46
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics (2007) 1.43
Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int (2014) 1.43
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (2013) 1.39
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis (2007) 1.27
Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg (2010) 1.22
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis (2012) 1.21
Overlap syndromes among autoimmune liver diseases. World J Gastroenterol (2008) 1.21
Bile salts and cholestasis. Dig Liver Dis (2010) 1.16
Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci (2006) 1.16
Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology (2005) 1.15
Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology (2014) 1.13
Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol (2002) 1.11
A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology (2012) 1.11
Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis (2004) 1.09
Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem (2008) 1.08
Antimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis-like disease in mouse models. Hepatology (2013) 1.07
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. J Biol Chem (2003) 1.05
Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol (2006) 1.05
Testicular inflammation as a new manifestation of IgG4-associated disease. Urology (2013) 1.02
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol (2012) 1.00
Mediators of pruritus during cholestasis. Curr Opin Gastroenterol (2011) 0.99
Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion (2009) 0.97
Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol (2005) 0.95
Pathogenesis and treatment of pruritus in cholestasis. Drugs (2008) 0.93
Intrahepatic cholestasis of pregnancy--a heterogeneous group of pregnancy-related disorders? Hepatology (2006) 0.92
Budesonide in previously untreated autoimmune hepatitis. Liver Int (2005) 0.91
IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol (2015) 0.91
Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem Biophys Res Commun (2007) 0.91
Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology (2014) 0.91
Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol (2006) 0.90
Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology (2003) 0.90
Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology (2004) 0.89
Changes of voice and articulation in children with cochlear implants. Int J Pediatr Otorhinolaryngol (2002) 0.89
ABCB4 deficiency: A family saga of early onset cholelithiasis, sclerosing cholangitis and cirrhosis and a novel mutation in the ABCB4 gene. Hepatol Res (2010) 0.87
The emerging role of transport systems in liver function tests. Eur J Pharmacol (2011) 0.86
Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol (2008) 0.86
Predictors of premature delivery in patients with intrahepatic cholestasis of pregnancy. World J Gastroenterol (2007) 0.86
Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant (2007) 0.86
Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res (2007) 0.86
Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology (2006) 0.86
Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease. Scand J Gastroenterol (2008) 0.86
Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets. World J Gastroenterol (2006) 0.85
Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol (2006) 0.85
Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J (2007) 0.85
Phosphatidylinositol 3-kinase-dependent signaling modulates taurochenodeoxycholic acid-induced liver injury and cholestasis in perfused rat livers. Am J Physiol Gastrointest Liver Physiol (2005) 0.85
Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells. J Hepatol (2010) 0.85
Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn's disease--a comprehensive review. Clin Rev Allergy Immunol (2015) 0.84
Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. Hepatol Res (2003) 0.84
Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest (2006) 0.83
Effect of preoperative biliary drainage on coagulation and fibrinolysis in severe obstructive cholestasis. J Clin Gastroenterol (2010) 0.83
Polyinosinic acid blocks adeno-associated virus macrophage endocytosis in vitro and enhances adeno-associated virus liver-directed gene therapy in vivo. Hum Gene Ther (2013) 0.83
Liver failure in adult Still's disease during corticosteroid treatment. Eur J Gastroenterol Hepatol (2003) 0.82
Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis (2014) 0.82
Advances in pathogenesis and treatment of pruritus. Clin Liver Dis (2012) 0.82
The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. Curr Drug Targets (2011) 0.82
Biomarkers for disease progression of primary sclerosing cholangitis. Curr Opin Gastroenterol (2015) 0.82
Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology (2010) 0.82
Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma. Inflamm Bowel Dis (2013) 0.82
Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol (2005) 0.82
Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. Hepatol Res (2003) 0.82
The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology (2010) 0.81
Are pigs more human than mice? J Hepatol (2009) 0.81
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol (2017) 0.81
Tauroursodeoxycholic acid mobilizes alpha-PKC after uptake in human HepG2 hepatoma cells. Eur J Clin Invest (2002) 0.81
Cross-sectional imaging findings in congenital intestinal lymphangiectasia. J Comput Assist Tomogr (2002) 0.81
Decreased expression of breast cancer resistance protein in the duodenum in patients with obstructive cholestasis. Digestion (2006) 0.81
Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma. Hepatology (2014) 0.81
When bile acids don't get amidated. Gastroenterology (2013) 0.80
Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Rev Mol Diagn (2009) 0.80
The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis. Biochem Biophys Res Commun (2005) 0.80
Targeting the ABCB4 gene to control cholesterol homeostasis. Expert Opin Ther Targets (2011) 0.80
Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA. Hepatology (2015) 0.79
Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol (2005) 0.79
Serum Autotaxin Activity Correlates With Pruritus in Pediatric Cholestatic Disorders. J Pediatr Gastroenterol Nutr (2016) 0.79
Prognostic value of 2D echocardiography in patients presenting with acute chest pain and non-diagnostic ECG for ST-elevation myocardial infarction. Int J Cardiol (2002) 0.79
Role of mitogen-activated protein kinases in tauroursodeoxycholic acid-induced bile formation in cholestatic rat liver. Hepatol Res (2008) 0.79
Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol (2014) 0.79
Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr Opin Lipidol (2013) 0.79
Extrahepatic manifestations of cholestasis. J Gastroenterol Hepatol (2002) 0.79
Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. Liver Int (2013) 0.79
Biliary bicarbonate secretion constitutes a protective mechanism against bile acid-induced injury in man. Dig Dis (2011) 0.78